{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:20Z","timestamp":1792831040184,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018554","name":"Science and Technology Program of Gansu Province","doi-asserted-by":"publisher","award":["23ZDFA003"],"award-info":[{"award-number":["23ZDFA003"]}],"id":[{"id":"10.13039\/501100018554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["lzujbky-2025-it64"],"award-info":[{"award-number":["lzujbky-2025-it64"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32571422"],"award-info":[{"award-number":["32571422"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110601","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:46:38Z","timestamp":1791503198000},"page":"110601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Benzisothiazole derivatives as KRAS G12C inhibitors for potential treatment of non-small cell lung cancer"],"prefix":"10.1016","volume":"183","author":[{"given":"Lei","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Juan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Ya","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Sheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Wu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2026.110601_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2026.110601_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120707","article-title":"Lung cancer biomarkers","volume":"580","author":"Mangang","year":"2026","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110601_bb0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cac2.12505","article-title":"Management of locally advanced non-small cell lung cancer: state of the art and future directions","volume":"44","author":"Miao","year":"2024","journal-title":"Cancer Commun. (Lond.)"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110601_bb0020","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110601_bb0025","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41589-024-01683-5","article-title":"Targeting Smurf1 to block PDK1-Akt signaling in KRAS-mutated colorectal cancer","volume":"21","author":"Peng","year":"2025","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110601_bb0030","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2147\/PPA.S296747","article-title":"Adherence to adjuvant tamoxifen in Mexican young women with breast cancer","volume":"15","author":"Martinez-Cannon","year":"2021","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.bioorg.2026.110601_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104228","article-title":"KRAS G12C-mutant driven non-small cell lung cancer (NSCLC)","volume":"195","author":"Rosell","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bioorg.2026.110601_bb0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.csbj.2019.12.004","article-title":"The current understanding of KRAS protein structure and dynamics","volume":"18","author":"Pantsar","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110601_bb0045","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.apsb.2019.03.002","article-title":"Targeting the untargetable KRAS in cancer therapy","volume":"9","author":"Liu","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110601_bb0050","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"19","key":"10.1016\/j.bioorg.2026.110601_bb0055","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1016\/j.bpj.2022.06.035","article-title":"Exploring CRD mobility during RAS\/RAF engagement at the membrane","volume":"121","author":"Nguyen","year":"2022","journal-title":"Biophys. J."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110601_bb0060","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10555-020-09918-2","article-title":"Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation","volume":"39","author":"Buday","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110601_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0789-x","article-title":"KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target","volume":"17","author":"Rom\u00e1n","year":"2018","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110601_bb0070","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s10555-020-09918-2","article-title":"Novel regulation of Ras proteins by direct tyrosine phosphorylation and dephosphorylation","volume":"39","author":"Buday","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110601_bb0075","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/nsmb.3275","article-title":"One-way membrane trafficking of SOS in receptor-triggered Ras activation","volume":"23","author":"Christensen","year":"2016","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110601_bb0080","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cellsig.2007.10.002","article-title":"The molecular functions of Shp2 in the Ras\/mitogen-activated protein kinase (ERK1\/2) pathway","volume":"20","author":"Dance","year":"2008","journal-title":"Cell. Signal."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110601_bb0085","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1111\/j.1349-7006.2009.01257.x","article-title":"Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation","volume":"100","author":"Matozaki","year":"2009","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110601_bb0090","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","article-title":"GEFs and GAPs: critical elements in the control of small G proteins","volume":"129","author":"Bos","year":"2007","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110601_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2022.11.016","article-title":"A comparative analysis of RAS variants in patients with disorders of somatic mosaicism","volume":"25","author":"Claire Hou","year":"2023","journal-title":"Genet. Med."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110601_bb0100","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1002\/ajmg.a.62356","article-title":"Novel findings and expansion of phenotype in a mosaic RASopathy caused by somatic KRAS variants","volume":"185","author":"Chang","year":"2021","journal-title":"Am. J. Med. Genet. A"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110601_bb0105","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1634\/theoncologist.2015-0084","article-title":"Targeting the KRAS pathway in non-small cell lung Cancer","volume":"21","author":"Tomasini","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110601_bb0110","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7477","key":"10.1016\/j.bioorg.2026.110601_bb0115","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.110601_bb0120","doi-asserted-by":"crossref","unstructured":"JJanes, M. R., Zhang, J., Li, L. S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., Feng, J., Chen, J. H., Li, S., Li, S., Long, Y. O., Thach, C., Liu, Y., Zarieh, A., Ely, T., Kucharski, J. M., Liu, Y, Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor, Cell, 2018, 172(3): 578\u2013589. e17, doi:https:\/\/doi.org\/10.1016\/j.cell.2018.01.006.","DOI":"10.1016\/j.cell.2018.01.006"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110601_bb0125","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110601_bb0130","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"issue":"15","key":"10.1016\/j.bioorg.2026.110601_bb0135","doi-asserted-by":"crossref","first-page":"15386","DOI":"10.1021\/acs.jmedchem.4c03183","article-title":"Discovery of fulzerasib (GFH925) for the treatment of KRAS G12C-mutated solid tumors","volume":"68","author":"Jiang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110601_bb0140","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jtho.2023.03.015","article-title":"D-1553 (Garsorasib), a potent and selective inhibitor of KRASG12C in patients with NSCLC: phase 1 study results","volume":"18","author":"Li","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110601_bb0145","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41591-024-03401-z","article-title":"Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial","volume":"31","author":"Shi","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.110601_bb0150","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/JCO.2025.43.16_suppl.8520","article-title":"Sosimerasib monotherapy in patients with previously treated KRAS G12C\u2013mutated non-small cell lung cancer: primary results of a phase 2 study","volume":"43","author":"Zhong","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110601_bb0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Sermann","year":"2025","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110601_bb0160","doi-asserted-by":"crossref","DOI":"10.6023\/cjoc202311021","article-title":"Synthesis and activity study of 1, 2-benzisothiazol-3-one derivatives","volume":"44","author":"Wang","year":"2024","journal-title":"Chin. J. Org. Chem."},{"key":"10.1016\/j.bioorg.2026.110601_bb0165","series-title":"KRAS G12C inhibitors and methods of using the same","author":"Lanman","year":"2018"},{"key":"10.1016\/j.bioorg.2026.110601_bb0170","series-title":"KRAS G12C inhibitors and methods of using the same","author":"Lanman","year":"2018"},{"key":"10.1016\/j.bioorg.2026.110601_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107467","article-title":"Discovery of novel coumarin-based KRAS G12C inhibitors from virtual screening and rational structural optimization","volume":"148","author":"Shi","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110601_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117581","article-title":"Discovery of ASP6918, a KRAS G12C inhibitor: synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors","volume":"98","author":"Imaizumi","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110601_bb0185","series-title":"Quinazoline derivative, preparation method therefor and use thereof","author":"Xie","year":"2022"},{"issue":"13","key":"10.1016\/j.bioorg.2026.110601_bb0190","doi-asserted-by":"crossref","first-page":"6677","DOI":"10.1021\/acs.jmedchem.0c00785","article-title":"Hitting KRAS when it\u2019s down","volume":"63","author":"Gabizon","year":"2020","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110601_bb0195","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1021\/acschembio.4c00217","article-title":"Contribution of noncovalent recognition and reactivity to the optimization of covalent inhibitors: a case study on KRasG12C","volume":"19","author":"P\u00e9czka","year":"2024","journal-title":"ACS Chem. Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110601_bb0200","article-title":"Structure-based design and synthesis of novel highly potent and selective KRASG12C inhibitors","volume":"302","author":"Gao","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2026.110601_bb0205","doi-asserted-by":"crossref","first-page":"11024","DOI":"10.1021\/acs.jmedchem.4c00572","article-title":"Discovery of MK-1084: an orally bioavailable and low-dose KRASG12C inhibitor","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110601_bb0210","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","article-title":"Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state","volume":"6","author":"Patricelli","year":"2016","journal-title":"Cancer Discov."},{"issue":"897","key":"10.1016\/j.bioorg.2026.110601_bb0215","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.adt6552","article-title":"Proteomic analyses identify targets, pathways, and cellular consequences of oncogenic KRAS signaling","volume":"18","author":"Kabella","year":"2025","journal-title":"Sci. Signal."},{"key":"10.1016\/j.bioorg.2026.110601_bb0220","doi-asserted-by":"crossref","unstructured":"Ito, M., Miyata, Y., Hirano, S., Morihara, N., Takemoto, M., Irisuna, F., Kushitani, K., Suda, K., Soh, J., Takeshima, Y., Tsutani, Y., Okada, M. Dual inhibition of GTP-bound KRAS and mTOR in lung adenocarcinoma and squamous cell carcinoma harboring KRAS G12C. Cell Commun. Signal 2025, 23(1):220. https:\/\/ doi.org.\/https:\/\/doi.org\/10.1186\/s12964-025-02187-y.","DOI":"10.1186\/s12964-025-02187-y"},{"key":"10.1016\/j.bioorg.2026.110601_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-50063-z","article-title":"Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer","volume":"15","author":"Kitai","year":"2024","journal-title":"Nat. Commun."},{"issue":"41","key":"10.1016\/j.bioorg.2026.110601_bb0230","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade3816","article-title":"Acquired resistance to KRAS G12C small-molecule inhibitors via genetic\/nongenetic mechanisms in lung cancer","volume":"9","author":"Mohanty","year":"2023","journal-title":"Sci. Adv."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110601_bb0235","article-title":"Discovery of novel pyrimidine-based KRAS-G12C inhibitors with potent anti-NSCLC activity via virtual screening and structure optimization","volume":"302","author":"Shi","year":"2026","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110601_bb0240","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12943-020-01202-9","article-title":"Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance","volume":"19","author":"Zhang","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.110601_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106412","article-title":"1H-indazoles derivatives targeting PI3K\/AKT\/mTOR pathway: synthesis, anti-tumor effect and molecular mechanism","volume":"133","author":"Wang","year":"2023","journal-title":"Bioorg. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:01:46Z","timestamp":1792828906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826011375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":49,"alternative-id":["S0045206826011375"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110601","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benzisothiazole derivatives as KRAS G12C inhibitors for potential treatment of non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110601"}}